Symbol="EIGR"
AssetType="Common Stock"
Name="Eiger Biopharmaceuticals Inc"
Description="Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. The company is headquartered in Palo Alto, California."
CIK="1305253"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2155 PARK BOULEVARD, PALO ALTO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="30170300"
EBITDA="-92890000"
PERatio="None"
PEGRatio="0"
BookValue="0.796"
DividendPerShare="0"
DividendYield="0"
EPS="-1.93"
RevenuePerShareTTM="0.34"
ProfitMargin="0"
OperatingMarginTTM="-6.24"
ReturnOnAssetsTTM="-0.461"
ReturnOnEquityTTM="-1.463"
RevenueTTM="14929000"
GrossProfitTTM="11647000"
DilutedEPSTTM="-1.93"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.541"
AnalystTargetPrice="3.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.551"
PriceToBookRatio="0.76"
EVToRevenue="8.36"
EVToEBITDA="0.247"
Beta="1.714"
num_52WeekHigh="9.89"
num_52WeekLow="0.527"
num_50DayMovingAverage="0.874"
num_200DayMovingAverage="1.851"
SharesOutstanding="44296400"
DividendDate="None"
ExDividendDate="None"
symbol="EIGR"
open="0.70"
high="0.72"
low="0.67"
price="0.71"
volume="105448.00"
latest_trading_day="2023-08-03"
previous_close="0.70"
change="0.01"
change_percent="1.9200%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="82"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="18"
Volume_recent_avg="439574"
Change_recent_avg="-0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-1.1"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="18"
Aroon_momentum_negative="82"
image_negative_thumbnail_id_1="126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0050.jpeg"
image_negative_thumbnail_id_2="515"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0090.jpeg"
image_neutral_thumbnail_id_1="523"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_neutral_thumbnail_id_2="582"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_positive_thumbnail_id_1="694"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0014.jpeg"
image_positive_thumbnail_id_2="968"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0130.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
